Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients

B. Trimarco, G. Rosiello, D. Sarno, G. Lorino, S. Rubattu, N. DeLuca, M. Volpe

Research output: Contribution to journalArticlepeer-review

Abstract

In patients with essential hypertension, left ventricular hypertrophy (LVH) increases the risk for cardiovascular morbidity and mortality. Thus its reversal represents one of the principal endpoints of antihypertensive treatment. We assessed the cardiovascular effects of 1-year antihypertensive treatment with rilmenidine (1 or 2 mg/day orally), a new oxazoline with a potent antihypertensive action that acts selectively through imidazoline-preferring receptors. In 11 hypertensive patients (mean age, 49 ± 2 years) with LVH, we measured systemic hemodynamics, large artery compliance, cardiac anatomy, and endocrine function. Patients underwent M-mode and 2-dimensional echocardiography as well as Doppler and peripheral pulsed Doppler flowmetry, determination of plasma atrial natriuretic factor (ANF) levels and renin activity (PRA), and of 24-hour urinary electrolyte and creatinine excretion in control conditions (systolic/diastolic blood pressure, 148 ± 3 102 ± 1 mm Hg), 4 weeks after blood pressure normalization ( 131 ± 2 84 ± 2 mm Hg; p <0.01), after 1 year of satisfactory antihypertensive treatment ( 142 ± 3 90 ± 1 mm Hg; p 4/dyne; p 4/ dyne; p 2 body surface area; p

Original languageEnglish
JournalThe American Journal of Cardiology
Volume74
Issue number13
DOIs
Publication statusPublished - Dec 22 1994

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients'. Together they form a unique fingerprint.

Cite this